Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial [Phase 3]
Phase 3 PIRAMID trial evaluating adding pirtobrutinib to standard therapy for newly diagnosed Richter transformation (transformed CLL/SLL to…
-
FDA approval · 2025-10-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
FDA approval · 2025-10-17FDA Approved: GAZYVA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for GAZYVA (obinutuzumab) from Genentech to expand its approved indications.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
Phase 2 clinical trial update assessing changes in disease activity and adverse events when oral venetoclax is combined with intravenous obi…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients [Phase 1]
Phase 1 study assessing rituximab plus high-dose methylprednisolone debulking before venetoclax in patients with chronic lymphocytic leukemi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
A Phase II randomized trial evaluating a Bruton tyrosine kinase inhibitor with or without venetoclax in veterans with chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL [Phase 1, Phase 2]
A Phase Ib study of the selective PKC-β inhibitor MS-553 in patients with refractory or relapsed chronic lymphocytic leukemia or small lymph…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL [Phase 2]
Phase 2 trial evaluating a combination of zanubrutinib, obinutuzumab, and sonrotoclax in previously untreated chronic lymphocytic leukemia a…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 [Phase 1]
A Phase 1 clinical trial update describing CD19-targeted CAR T-cell immunotherapy for high-risk or relapsed CD19+ acute lymphoblastic leukem…
-
EMA approval · 2025-09-19EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB
EMA authorised Calquence (acalabrutinib) for use in chronic lymphocytic leukemia and small lymphocytic lymphoma; the product is manufactured…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Global Trial in APG2575 for Patients With CLL/SLL [Phase 3]
Global Phase 3 trial of APG2575 in chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies [Phase 1, Phase 2]
GT719 Injection is being studied in a Phase 1/2 trial for recurrent or refractory CD19-positive adult B-cell malignancies, with recruitment …
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS other · 2025-09-08Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) [Phase 1, Phase 2]
This clinical trial update indicates that Nemtabrutinib (MK-1026) is being studied for relapsed or refractory hematologic malignancies in a …
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
Post-marketing surveillance update for Calquence (acalabrutinib) in relapsed or refractory chronic lymphocytic leukemia, including small lym…
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial update assessing lenalidomide in combination with a vaccine therapy for patients with early-stage asymptomatic chroni…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This [Phase 2]
Phase 2 trial evaluating LP-168 in combination with obinutuzumab for chronic lymphocytic leukemia/small lymphocytic lymphoma and related var…
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL [NA]
This clinical trial update describes a study evaluating the combination of anti-CD19 CAR-T therapy with a BTK inhibitor to treat newly diagn…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: 64Cu-LLP2A for Imaging Hematologic Malignancies [EARLY_Phase 1]
Phase 1 imaging trial evaluating 64Cu-LLP2A in hematologic malignancies is currently recruiting, targeting multiple myeloma and various lymp…
-
CLINICAL_TRIALS research · 2025-07-17Clinical Trial Update: CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1]
This clinical trial update announces a Phase 1 study of CAP-100 for relapsed/refractory chronic lymphocytic leukemia and small lymphocytic l…
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL [Phase 1]
Phase 1 clinical trial evaluating autologous CD19-specific CAR T cells (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma, chronic …